Development and multicenter validation of an LC–MS-based bioanalytical method for antisense therapeutics

Author:

Sun Yuchen1ORCID,Nitta Shin-ichiro2,Saito Kosuke1ORCID,Hosogai Ryuta2,Nakai Keiko2,Goda Ryoya3,Shimizu Hisao4ORCID,Fujita Hisashi4,Kakehi Masaaki4,Murata Kazuyuki5,Yamaguchi Takeru5,Okuzono Takeshi6,Yamane Shinichi6,Kawabata Mitsuhiko7,Matsunuma Takayuki8,Takahara Kentaro8,Kato Noriko9,Yamada Masaki9,Yoshida Tokuyuki10,Inoue Takao10,Saito Yoshiro1ORCID

Affiliation:

1. Division of Medicinal Safety Science, National Institute of Health Sciences, Kanagawa, 210-9501, Japan

2. LSI Medience Corporation, Tokyo, 105-0023, Japan

3. Daiichi Sankyo Company Ltd, Tokyo, 140-8710, Japan

4. Takeda Pharmaceutical Company Ltd, Kanagawa, 251-8555, Japan

5. Sumika Chemical Analysis Service Ltd, Osaka, 554-0022, Japan

6. Sekisui Medical Co. Ltd, Tokyo, 103-0027, Japan

7. Shin Nippon Biomedical Laboratories Ltd, Tokyo, 104-0044, Japan

8. Thermo Fisher Scientific KK, Kanagawa, 221-0022, Japan

9. Shimadzu Corporation, Kyoto, 140-8710, Japan

10. Division of Molecular Target & Gene Therapy Products, National Institute of Health Sciences, Kanagawa, 210-9501, Japan

Abstract

Background: Many bioanalytical methods for antisense oligonucleotides (ASOs) using LC–MS have been reported. However, no data have been available on the reproducibility and robustness of a single bioanalytical method for ASOs. As such, in the current study, we evaluated the reproducibility and robustness of LC–MS-based bioanalytical methods for ASOs in multiple laboratories. Methods/Results: Seven independent laboratories were included in this study. Mipomersen was measured by ion-pairing LC–MS (IP-LC–MS) as a model ASO using different LC–MS. The validation results of calibration curve, accuracy, precision and selectivity met the criteria of conventional bioanalytical method validation guidelines using LC/GC–MS for drugs in all laboratories. Meanwhile, carryover (>20%) was detected in three laboratories. Conclusion: We first demonstrated the multicenter-validated IP-LC–MS bioanalytical method for ASOs. Our data showed that the method was sensitive, robust and reproducible. However, the occurrence of carryover should be carefully monitored in its future application.

Funder

Japan Agency for Medical Research and Development

Publisher

Future Science Ltd

Subject

Medical Laboratory Technology,Clinical Biochemistry,General Pharmacology, Toxicology and Pharmaceutics,General Medicine,Analytical Chemistry

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Developmental Strategies and Method Validation of LC-MS-Based Bioanalytical Methods for Oligonucleotide Therapeutics;Journal of the Mass Spectrometry Society of Japan;2023-06-01

2. LC-MSを用いた合成オリゴ核酸の不純物確認;Journal of the Mass Spectrometry Society of Japan;2023-06-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3